4.1 Review

Anti psychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia - A systematic review

Journal

JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
Volume 28, Issue 2, Pages 203-209

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/JCP.0b013e318166c4d5

Keywords

-

Funding

  1. NCRR NIH HHS [KL2 RR024990] Funding Source: Medline
  2. NIMH NIH HHS [P20 MH-66054, P20 MH066054-05, P20 MH066054] Funding Source: Medline
  3. NATIONAL CENTER FOR RESEARCH RESOURCES [KL2RR024990] Funding Source: NIH RePORTER
  4. NATIONAL INSTITUTE OF MENTAL HEALTH [P20MH066054] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Objectives: Newer atypical antipsychotics have been reported to cause a lower incidence of extrapyramidal side effects (EPS) than conventional agents. This review is to compare antipsychotic-induced EPS relative to placebo in bipolar disorder (BPD) and schizophrenia. Methods: English-language literature cited in Medline was searched with terms antipsychotics, placebo-controlled trial, and bipolar disorder or schizophrenia and then with antipsychotic (generic/brand name), safety, akathisia, EPS, or anticholinergic use, bipolar mania/depression, BPD, or schizophrenia, and randomized clinical trial. Randomized, double-blind, placebo-controlled, monotherapy studies with comparable doses in both BPD and schizophrenia were included. Absolute risk increase and number needed to treat to harm (NNTH) for akathisia, overall EPS, and anticholinergic use relative to placebo were estimated. Results: Eleven trials in mania, 4 in bipolar depression, and 8 in schizophrenia were included. Haloperidol significantly increased the risk for akathisia, overall EPS, and anticholinergic use in both mania and schizophrenia, with a larger magnitude in mania, an NNTH for akathisia of 4 versus 7, EPS of 3 versus 5, and anticholinergic use of 2 versus 4, respectively Among atypical antipsychotics, only ziprasidone significantly increased the risk for overall EPS and anticholinergic use in both mania and schizophrenia, again with larger differences in mania, an NNTH for overall EPS of I 1 versus 19, and anticholinergic use of 5 versus 9. In addition, risks were significantly increased for overall EPS (NNTH = 5) and anticholinergic use (NNTH = 5) in risperidone-treated mania, akathisia in aripiprazole-treated mania (NNTH = 9) and bipolar depression (NNTH = 5), and overall EPS (NNTH = 19) in quetiapine-treated bipolar depression. Conclusions: Bipolar patients, especially in depression, were more vulnerable to having acute antipsychotic-induced movement disorders than those with schizophrenia.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available